What is Perspective Therapeutics Inc (CATX)?
Perspective Therapeutics Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer and other diseases. The company utilizes a proprietary platform to identify and develop novel antibody-drug conjugates and other biologics aimed at improving treatment efficacy and safety. Its research and development efforts concentrate on creating precision medicines that address unmet medical needs by selectively targeting disease-specific biomarkers. Perspective Therapeutics Inc operates within the biopharmaceutical sector, engaging in preclinical and clinical studies to advance its pipeline of therapeutic candidates.
Perspective Therapeutics Inc Stock Price Today: Live Overview
The price today is shaped by active intraday trading in NCR Atleos Corp, now priced at $4.11. The session has seen price movements ranging from $4.02 to $4.18, with a daily change of -2.381%.
FAQ: Perspective Therapeutics Inc (CATX)
What is the current price of CATX stock?
The stock is currently valued at $4.11.
Does CATX pay dividends?
Perspective Therapeutics Inc does not pay dividends.
Does CATX have a formal corporate presence or regional headquarters in the UAE?
The company operates via partners and distributors in the UAE and lacks a registered office or subsidiary.
What is CATX best known for?
It is most famous for developing targeted therapies in oncology and neurology.
What assets are typically shown together with CATX?
Commonly shown alongside CATX: Franco Nevada - CAD, Acadia Healthcare Co Inc, Duke Capital Ltd
Latest shares articles



